Press Releases
Jan 23, 2023

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that Astellas and Sandoz AG ("Sandoz") have entered into an Asset Purchase Agreement, under...

Jan 20, 2023

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on January 19th...

Jan 19, 2023

Data shows investigational zolbetuximab reduced risk of progression or death by 24.9% Study evaluated patients with Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic...

EXPLORE ALL US PRESS RELEASES

Articles
Sep 20, 2022

Astellas was recently ranked in Seramount’s 2022 list of 100 Best Companies and Best Companies for Dads highlighting our commitment to creating a workplace where working parents are valued and...

Sep 20, 2022

Astellas ranked again in Seramount’s 2022 “100 Best Companies” list and Best Companies for Dads

Sep 13, 2022

C3 Prize Winner Shares How Her Father’s Experience with Cancer Inspired Her to Create New Patient App Astellas Pharma senior vice president and global head of Patient Centricity Dr. Anthony...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products